Glioblastoma: Synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 6, 2010, Pages 657-663

  Kast, R E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

aprepitant; CCR5; chemotherapy; cytokine; glioblastoma; maraviroc; neurokinin 1; substance P; synergism; translational medicine

Indexed keywords

APREPITANT; MARAVIROC; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROKININ 1 RECEPTOR; RANTES;

CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COUGHING; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG ERUPTION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; ENZYME ACTIVATION; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANTI-HIV AGENTS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CYCLOHEXANES; DRUG APPROVAL; DRUG INTERACTIONS; GLIOBLASTOMA; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 3; MORPHOLINES; PHOSPHORYLATION; RECEPTORS, CCR5; RECEPTORS, NEUROKININ-1; SIGNAL TRANSDUCTION; TRIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77956170074     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01148.x     Document Type: Review

References (53)

1. Navari RM, (2009) Pharmacological management of chemotherapy induced nausea and vomiting: focus on recent developments. Drugs, 69, 515-533.
2. Diemunsch P, Joshi GP, Brichant JF, (2009) Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. British Journal of Anaesthesia, 103, 7-13.
3. Lieberman-Blum SS, Fung HB, Bandres JC, (2008) Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clinical Therapeutics, 30, 1228-1250.
4. Soriano V, Geretti AM, Perno CF, et al. (2008) Optimal use of maraviroc in clinical practice. AIDS, 22, 2231-2240.
5. Lederman MM, Penn-Nicholson A, Cho M, Mosier D, (2006) Biology of CCR5 and its role in HIV infection and treatment. JAMA, 296, 815-826.
6. Chernova I, Lai JP, Li H, et al. (2009) Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R). Journal of Leukocyte Biology, 85, 154-164.
7. Kast RE, (2009) Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question. Clinical Translational Oncology, 11, 408-410.
8. Douglas SD, Lai JP, Tuluc F, Schwartz L, Kilpatrick LE, (2008) Neurokinin-1 receptor expression and function in human macrophages and brain: perspective on the role in HIV neuropathogenesis. Annals of the New York Academy of Sciences, 1144, 90-96.
9. Lim JK, Glass WG, McDermott DH, Murphy PM, (2006) CCR5: no longer a 'good for nothing' gene - chemokine control of West Nile virus infection. Trends in Immunology, 27, 308-312.
10. Suzuki S, Miyagi T, Chuang LF, Yau PM, Doi RH, Chuang RY, (2002) Chemokine receptor CCR5: polymorphism at protein level. Biochemical and Biophysical Research Communications, 296, 477-483.
11. Aramori I, Ferguson SS, Bieniasz PD, Zhang J, Cullen B, Cullen MG, (1997) Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. EMBO Journal, 16, 4606-4616.
12. Zhao J, Ma L, Wu YL, Wang P, Hu W, Pei G, (1998) Chemokine receptor CCR5 functionally couples to inhibitory G proteins and undergoes desensitization. Journal of Cellular Biochemistry, 71, 36-45.
13. Leach K, Charlton SJ, Strange PG, (2007) Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5. Biochemical Pharmacology, 74, 881-890.
14. Dhami H, Fritz CE, Gankin B, et al. (2009) The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies. Journal of Clinical Pharmacy and Therapeutics, 34, 147-160.
15. Kalev I, Kaasik A, Zarkovski A, Mikelsaar AV, (2006) Chemokine receptor CCR5 expression in in vitro differentiating human fetal neural stem/progenitor and glioblastoma cells. Neuroscience Letters, 394, 22-27.
16. Kouno J, Nagai H, Nagahata T, et al. (2004) Up-regulation of CC chemokine, CCL3L1, and receptors, CCR3, CCR5 in human glioblastoma that promotes cell growth. Journal of Neuro-Oncology, 70, 301-307.
17. Ishii N, Tada M, Sakuma S, Sawamura Y, Shinohe Y, Abe H, (1998) Human astrocytoma cells are capable of producing macrophage inflammatory protein-1beta. Journal of Neuro-Oncology, 37, 17-23.
18. Sohy D, Parmentier M, Springael JY, (2007) Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. Journal of Biological Chemistry, 282, 30062-30069.
19. Springael JY, Le Minh PN, Urizar E, Costagliola S, Vassart G, Parmentier M, (2006) Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Molecular Pharmacology, 69, 1652-1661.
20. Milligan G, Smith NJ, (2007) Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends in Pharmacological Sciences, 28, 615-620.
21. Liang Y, Bollen AW, Gupta N, (2008) CC chemokine receptor-2A is frequently overexpressed in glioblastoma. Journal of Neuro-Oncology, 86, 153-163.
22. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB, (2008) Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunology, Immunotherapy, 57, 123-131.
23. Muñoz M, Rosso M, (2009) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Investigational New Drugs [Epub ahead of print] PubMed PMID: 19148578.
24. Yamaguchi K, Richardson MD, Bigner DD, Kwatra MM, (2005) Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta. Cancer Chemotherapy and Pharmacology, 56, 585-593. (Pubitemid 41425054)
25. Muñoz M, Rosso M, Aguilar FJ, González-Moles MA, Redondo M, Esteban F, (2008) NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Investigational New Drugs, 26, 111-118.
26. Lai JP, Ho WZ, Kilpatrick LE, Wang X, Tuluc F, Korchak HM, Douglas SD, (2006) Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation. Proceedings of the National Academy of Sciences of the United States of America, 103, 7771-7776.
27. Kast RE, Altschuler EL, (2006) Current drugs available now for interleukin-6 suppression as treatment adjunct in glioblastoma: anakinra, aprepitant, mirtazapine, and olanzapine. International Journal of Cancer Research, 4, 303-314.
28. Walker DK, Bowers SJ, Mitchell RJ, Potchoiba MJ, Schroeder CM, Small HF, (2008) Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica, 38, 1330-1339.
29. Kast RE, (2009) Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma. Journal of Neuro-Oncology, 94, 163-167.
30. Kast RE, (2007) Using blood brain barrier disruption by methamphetamine for drug delivery. Journal of Neuro-Oncology, 85, 109-110.
31. Wong ML, Prawira A, Kaye AH, Hovens CM, (2009) Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas. Journal of Clinical Neuroscience, 16, 1119-1130.
32. Lama G, Mangiola A, Anile C, et al. (2007) Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue. International Journal of Oncology, 30, 1333-1342.
33. May LT, Hill SJ, (2008) ERK phosphorylation: spatial and temporal regulation by G protein-coupled receptors. International Journal of Biochemistry and Cell Biology, 40, 2013-2017.
34. Maru SV, Holloway KA, Flynn G, Lancashire CL, Loughlin AJ, Male DK, Romero IA, (2008) Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. Journal of Neuroimmunology, 199, 35-45.
35. Lopez-Gines C, Gil-Benso R, Benito R, et al. (2008) The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathology, 28, 507-515.
36. Lawrence MC, Jivan A, Shao C, et al. (2008) The roles of MAPKs in disease. Cell Research, 18, 436-442.
37. Gan HK, Kaye AH, Luwor RB, (2009) The EGFRvIII variant in glioblastoma multiforme. Journal of Clinical Neuroscience, 16, 748-752.
38. Balmanno K, Cook SJ, (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death and Differentiation, 16, 368-377.
39. Ihnatko R, Kubes M, Takacova M, et al. (2006) Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. International Journal of Oncology, 29, 1025-1033.
40. Lin HY, Sun M, Tang HY, et al. (2009) L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. American Journal of Physiology and Cell Physiology, 296, C980-C991.
41. Davis FB, Tang HY, Shih A, et al. (2006) Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Research, 66, 7270-7275.
42. Zagzag D, Esencay M, Mendez O, et al. (2008) Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. American Journal of Pathology, 173, 545-560.
43. Charalambous C, Chen TC, Hofman FM, (2006) Characteristics of tumor-associated endothelial cells derived from glioblastoma multiforme. Neurosurgical Focus, 20, E22.
44. Berger Y, Dehmlow H, Blum-Kaelin D, Kitas EA, Löffler BM, Aebi JD, Juillerat-Jeanneret L, (2005) Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. Journal of Medicinal Chemistry, 48, 483-498.
45. Tencheva TsS, Panov IR, (2008) Intracerebral development of transplanted glioblastoma C6 cells in rats after preliminary exposure to neuropeptides and an MAPK inhibitor. Neuroscience and Behavioral Physiology, 38, 913-916.
46. Juillerat-Jeanneret L, Celerier J, Bernasconi CC, et al. (2004) Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. British Journal of Cancer, 90, 1059-1068.
47. Ariza A, Fernandez LA, Inagami T, Kim JH, Manuelidis EE, (1988) Renin in glioblastoma multiforme and its role in neovascularization. American Journal of Clinical Pathology, 90, 437-441.
48. Kast RE, (2009) Glioblastoma chemotherapy adjunct: growth factor deprivation via potent serotonin receptor 7 inhibition with currently marketed psychiatric medicines. Journal of experimental therapeutics & oncology.
49. Yamazaki H, Fukui Y, Ueyama Y, Tamaoki N, Kawamoto T, Taniguchi S, Shibuya M, (1988) Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Molecular and Cellular Biology, 8, 1816-1820.
50. Lefranc F, Rynkowski M, DeWitte O, Kiss R, (2009) Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Advances and Technical Standards in Neurosurgery, 34, 3-35.
51. Lefranc F, Sadeghi N, Camby I, Metens T, Dewitte O, Kiss R, (2006) Present and potential future issues in glioblastoma treatment. Expert Review of Anticancer Therapy, 6, 719-732.
52. Kuhn SA, Mueller U, Hanisch UK, et al. (2009) Glioblastoma cells express functional cell membrane receptors activated by daily used medical drugs. Journal of Cancer Research and Clinical Oncology, 135, 1729-1745.
53. Carapancea M, Alexandru O, Fetea AS, et al. (2009) Growth factor receptors signaling in glioblastoma cells: therapeutic implications. Journal of Neuro-Oncology, 92, 137-147.